September 2025 - Corcept Therapeutics

Mifepristone, a Glucocorticoid Receptor Antagonist, Reduced HbA1c and Body Weight in Difficult-to-control Type 2 Diabetes with Hypercortisolism: The CATALYST Prevalence and Treatment Trial

September 17, 2025

DeFronzo, et al. • 2025 • EASD 2025

Difficult-to-Control Type 2 Diabetes and a Post-Dexamethasone Suppression Test Cortisol of 1.2–1.8 µg/dL: Findings From a Large Prospective Study

September 17, 2025

Buse, et al. • 2025 • EASD 2025